Journal article
Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue
Cancer research (Chicago, Ill.), Vol.67(24), pp.11798-11810
12/15/2007
DOI: 10.1158/0008-5472.CAN-06-4471
PMID: 18089810
Abstract
Constitutively active RAS small GTpases promote the genesis of human cancers. An important goal in cancer biology is to identify means of countervailing activated RAS signaling to reverse malignant transformation. Oncogenic K-PUS mutations are found in virtually all pancreatic adenocarcinomas, making the RAS pathway an ideal target for therapeutic intervention. How to best contravene hyperactivated RAS signaling has remained elusive in human pancreatic cancers. Guided by the Drosophila studies, we reasoned that a downstream mediator of RAS signals might be a suitable anti-RAS target. The E3 ubiquitin ligase seven in absentia (SINA) is an essential downstream component of the Drosophila RAS signal transduction pathway. Thus, we determined the roles of the conserved human homologues of SINA, SIAHs, in mammalian RAS signaling and RAS-mediated tumorigenesis. We report that similar to its Drosophila counterpart, human SIAH is also required for oncogenic RAS signaling in pancreatic cancer. Inhibiting SIAH-dependent proteolysis blocked RAS-mediated focus formation in fibroblasts and abolished the tumor growth of human pancreatic cancer cells in soft agar as well as in athymic nude mice. Given the high level of conservation of RAS and SIAH function, our study provides useful insights into altered proteolysis in the RAS pathway in tumor initiation, progression, and oncogenesis. By targeting SIAH, we have found a novel means to contravene oncogenic RAS signaling and block RAS-mediated transformation/tumorigenesis. Thus, SIAH may offer a novel therapeutic target to halt tumor growth and ameliorate RAS-mediated pancreatic cancer.
Details
- Title: Subtitle
- Inhibition of RAS-mediated transformation and tumorigenesis by targeting the downstream E3 ubiquitin ligase seven in absentia homologue
- Creators
- Rebecca L. Schmidt - Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USACheol Hong Park - Mayo ClinicAtique U. Ahmed - Mayo ClinicJustin H. Gundelach - Mayo ClinicNanette R. Reed - Mayo ClinicShen Cheng - Mayo Clin, Coll Med, Mayo Clin Canc Ctr, Dept Surg, Rochester, MN USABruce E. Knudsen - Mayo ClinicAmy H. Tang - Mayo Clinic
- Resource Type
- Journal article
- Publication Details
- Cancer research (Chicago, Ill.), Vol.67(24), pp.11798-11810
- Publisher
- Amer Assoc Cancer Research
- DOI
- 10.1158/0008-5472.CAN-06-4471
- PMID
- 18089810
- ISSN
- 0008-5472
- eISSN
- 1538-7445
- Number of pages
- 13
- Grant note
- R01GM069922 / NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS) GM 069922 / NIGMS NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of General Medical Sciences (NIGMS)
- Language
- English
- Date published
- 12/15/2007
- Academic Unit
- Surgery
- Record Identifier
- 9984701642502771
Metrics
3 Record Views